NYMXF: Nymox Pharmaceutical Corporation Stock

SIC 2835 – In Vitro and In Vivo Diagnostic Substances

Valuation
Market Cap ($M) 17.96
Enterprise Value ($M) 21.17
Book Value ($M) -6.78
Book Value / Share -0.07
Price / Book -2.65
NCAV ($M) -6.78
NCAV / Share -0.07
Price / NCAV -2.65

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -7.16
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.09
Current Ratio 0.09

Balance Sheet (mrq) ($M)
Current Assets 0.65
Assets 0.65
Liabilities 7.43
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -4.28
Net Income -4.49

Cash Flow Statement (mra) ($M)
Cash From Operations -2.60
Cash from Investing 0.00
Cash from Financing 2.60

(click for more detail)
Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

Similar Companies
NVYTF – Novacyt S.A. NWBO – Northwest Biotherapeutics, Inc.
NXEN – Nexien BioPharma, Inc. OBSEF – ObsEva SA
OCEA – Ocean Biomedical, Inc.


Financial data and stock pages provided by
Fintel.io